Iveric Bio Inc Stock Price, News & Analysis

IVERIC bio (NASDAQ: ISEE) announced that President Pravin U. Dugel, M.D., will participate in a fireside chat at the UBS Global Healthcare Conference on May 23, 2022, at 10:45 a.m. Eastern Time. The event will be accessible via a live webcast on the Investor Events section of IVERIC's website, with an archived replay available for 30 days post-conference. IVERIC bio focuses on developing innovative treatments for retinal diseases, aiming to improve patient outcomes in conditions like age-related macular degeneration.

Iveric Bio (NASDAQ: ISEE) announced that President Pravin U. Dugel, M.D. will present a corporate overview at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The presentation will be available on-demand starting May 24 at 7:00 a.m. ET, and an archived replay will be accessible for 30 days afterward. Iveric Bio specializes in developing treatments for retinal diseases, aiming to improve patient outcomes for conditions like age-related macular degeneration.

IVERIC bio announced significant updates in its Q1 2022 results, highlighting the GATHER2 clinical trial nearing completion with a 94% milestone achieved. The company anticipates reporting topline data in Q3 2022, aiming for an NDA submission for Zimura®, a complement inhibitor for geographic atrophy (GA). The injection fidelity rate exceeded expectations, targeting over 90%. Financially, Q1 net loss was $34.5 million, with R&D expenses rising to $22.6 million. The company holds approximately $345.7 million in cash, sufficient to fund operations into mid-2024.

Iveric Bio announced a post-hoc analysis of the GATHER1 clinical trial results for Zimura (avacincaptad pegol), assessing its impact on geographic atrophy (GA) lesion growth. The findings will be presented at the Retinal World Congress on May 13, 2022, in Fort Lauderdale, FL. The analysis shows consistent reduction in GA lesion growth in patients receiving Zimura compared to sham across all baseline distances from the foveal center. Zimura met its primary efficacy endpoint in GATHER1, and topline results from the ongoing GATHER2 trial are anticipated in Q3 2022, with potential FDA and EMA submissions following positive results.

Iveric Bio (NASDAQ: ISEE) announced on May 2, 2022, that it granted equity-based awards to six newly-hired, non-executive employees under its 2019 Inducement Stock Incentive Plan. These grants, approved by the compensation and talent strategy committee, included 156,000 non-statutory stock options and 13,500 restricted stock units, aimed at attracting talent. The stock options have an exercise price of $14.29 and a ten-year term, with a vesting schedule of four years. Iveric Bio focuses on developing treatments for retinal diseases.

Iveric Bio (NASDAQ: ISEE) is set to release its first quarter 2022 financial and operational results on May 4, 2022. The company's management will hold a live conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. Iveric Bio focuses on developing innovative treatments for retinal diseases. Interested participants can join the call by dialing in or accessing the live webcast through the company's investor relations website.

Iveric Bio, a biopharmaceutical company focused on retinal diseases, announced that Pravin U. Dugel, M.D., its President, will participate in a fireside chat at B. Riley Securities' Virtual Neuro & Ophthalmology Conference on April 28, 2022, at 9:00 a.m. ET. The event will be accessible via live webcast on the Iveric Bio website, with an archived replay available for 30 days following the conference. Iveric Bio aims to develop innovative treatments for retinal diseases, including age-related macular degeneration.

Iveric Bio (NASDAQ: ISEE) announced on April 1, 2022 the grant of equity-based awards to 21 new non-executive employees under its 2019 Inducement Stock Incentive Plan. This includes non-statutory stock options totaling 370,100 shares and 18,700 restricted stock units. The options have an exercise price of $17.79, vesting over four years. The initiative aims to attract talent and aligns with Nasdaq rules for employment compensation, emphasizing Iveric’s commitment to developing treatments for retinal diseases.

Iveric Bio (NASDAQ: ISEE) announced on March 1, 2022 the grant of equity-based awards to four new non-executive employees under its 2019 Inducement Stock Incentive Plan. These grants included stock options for 72,000 shares and 500 restricted stock units, incentivizing employee acceptance of roles. The stock options have an exercise price of $16.10 per share, with a vesting schedule spanning four years. The restricted stock units vest fully on September 1, 2022, contingent upon continued employment.